Factors predictive of virological failure on atazanavir in 310 HIV-infected patients.
We examined factors associated with virological failure in 310 HIV-infected patients receiving atazanavir (ATV). Independent links were identified with virological failure under ATV: virological failure previous history (P = 0.006) and ATV underdosing (P = 0.04). A maintenance therapy was protective (P = 0.01). The optimal therapeutic ranges of ATV concentration were found to be from 300 ng/ml (or 180 for patients treated with maintenance therapy) to 650 ng/ml for C24 and from 1000 ng/ml (or 500 for patients treated with maintenance therapy) to 2000 ng/ml for C12.
Service de Maladies Infectieuses et Tropicales, APHP Hôpital Tenon and Université Pierre et Marie Curie, France Paris, France. xavier.lescure@tnn.aphp.fr
François-Xavier
FX
Lescure
Jean-Marie
JM
Poirier
Jean-Luc
JL
Meynard
Jean-Baptiste
JB
Guiard-Schmid
Ouahiba
O
Zouai
Philippe
P
Bonnard
Laurence
L
Slama
Corinne
C
Amiel
Pierre-Marie
PM
Girard
Gilles
G
Pialoux
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D000069446:Atazanavir Sulfate; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D012372:ROC Curve; D019562:Viral Load; D055815:Young Adult
D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate